Brendan [Unknown]'s questions to OraSure Technologies Inc (OSUR) leadership • Q2 2025
Question
A representative for Patrick Donnelly at Citi inquired about the specifics of the Q3 revenue guidance, particularly the dynamics between the HIV and HCV platforms, and the potential for further gross margin leverage in 2025 from insourcing manufacturing. A follow-up question concerned the initial market traction and opportunity for the newly launched HemoCollect blood proteomics product.
Answer
CFO Kenneth McGrath stated that Q3 gross margin is expected to be consistent with Q2, with benefits from the manufacturing transition being volume-dependent and ramping up through 2026. He also noted that while HCV revenue is expected to be stable, international HIV orders will slow in Q3 as partners work through inventory. CEO Carrie Manner added that the Q3 guide reflects a reduction in revenue from the 'Together Take Me Home' program to $0.5 million from a typical $2 million run-rate. Regarding proteomics, Manner described enthusiastic customer engagement for the HemoCollect protein launch, highlighting its ability to stabilize proteins at room temperature and its broad applicability in research areas like oncology and neurology, with momentum expected to build into 2026.